• NSC-23766: Rac GTPase Inhibitor Workflow

  2026-09-03

  NSC-23766 is a practical Rac GTPase inhibitor for connecting Rac1 activity with apoptosis, migration, stemness, and endothelial barrier phenotypes. This workflow shows how to optimize dosing, distinguish biochemical from cellular potency, and extend single-agent studies into BRD4–RAC1 combination experiments.

• Tropisetron Hydrochloride Assay Workflows

  2026-09-03

  Tropisetron Hydrochloride supports receptor pharmacology, serotonin pathway studies, and transporter-focused renal assays in one adaptable workflow. This guide translates published OCT2/MATE1 findings into practical experiment design, controls, and troubleshooting steps for reliable in vitro data.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-09-02

  A 2025 Toxicology and Applied Pharmacology study identifies thymoquinone as a preclinical cardioprotective agent in a doxorubicin-treated mouse model. Its findings connect improved cardiac function with Nrf2/HO-1 activation, stronger antioxidant defenses, preserved mitochondria, and reduced ferroptosis-related injury.

• 6-FAM SE: Practical Fluorescent Labeling Workflows

  2026-09-02

  6-FAM SE combines amine-selective coupling with durable fluorescent conjugates for DNA, protein, peptide, and nanoparticle assay development. This guide turns the reagent into a practical workflow, from DMSO stock preparation and labeling to purification, quantitative QC, and careful translation into MOF-based nanomedicine studies.

• MG-132 in Proteasome, Apoptosis, and HCMV Assays

  2026-09-01

  MG-132, also known as Z-LLL-al, provides a cell-permeable way to connect proteasome activity with protein turnover, apoptosis, ROS, and cell-cycle phenotypes. This workflow also shows how it can be used cautiously to test whether HCMV UL88-associated MyD88 loss is sensitive to proteasome blockade.

• MMP-2-Responsive Liposome for Sequential Immunotherapy

  2026-09-01

  The reference study develops NLG919@Lip-pep1, an MMP-2-responsive liposome designed to deliver the PD-1 pathway-blocking peptide AUNP-12 before exposing a second tumor-targeting module carrying the IDO inhibitor NLG919. Its cascade-targeting strategy combines checkpoint inhibition with immunosuppressive microenvironment remodeling and improves antitumor activity in breast cancer models, while highlighting important requirements for translational nanomedicine.

• O-GlcNAc, HUWE1, and Ferroptosis in Preeclampsia

  2026-08-31

  This study identifies an O-GlcNAc–HUWE1–TfR1 pathway that links trophoblast protein modification to iron handling, ferroptosis, and syncytialization defects in preeclampsia. Its combination of placental analyses, O-GlcNAc modification proteomics, mechanistic validation, and mouse experiments provides a framework for examining how altered nutrient-sensitive signaling affects placental disease.

• Cyclic di-GMP as an Antitoxin in Biofilm Persistence

  2026-08-31

  Liao et al. identify cyclic di-GMP as a small-molecule antitoxin that restrains the genotoxic toxin HipH during biofilm development. Their findings connect adhesion-stage signaling with DNA double-strand breaks, genome instability, and antibiotic persistence, providing a mechanistic framework for studying biofilm resilience.

• A40926: From Biosynthetic Control to Assay Insight

  2026-08-30

  A40926 is a dalbavancin precursor with value beyond conventional antibacterial screening. This article connects its cell-wall mechanism and pathogen-specific MIC behavior with new evidence on pathway-specific regulatory genes, enabling more informed assay and fermentation decisions.

• RG108: A Practical Guide to DNMT Assays

  2026-08-29

  RG108 is a non-nucleosidic DNA methyltransferase inhibitor for studying DNA demethylation, tumor suppressor gene reactivation, and epigenetic gene regulation. This guide connects biochemical potency, cell-based assay design, formulation, and in vivo pharmacokinetic evidence.

• AZD1390: ATM Kinase Inhibitor Workflow

  2026-08-28

  AZD1390 enables mechanism-led ATM inhibition in radiation, replication-stress, and glioblastoma models. Its strongest differentiation is the ability to connect DNA damage response signaling with emerging REV1–DHX36 and G-quadruplex biology while preserving a practical, concentration-controlled workflow.

• STMN2 Depletion, Translation Deficits, and ALS Stress

  2026-08-28

  The reference study shows that neuronal STMN2 depletion can arise through proteasomal degradation, phosphorylation, stress-granule-associated translation repression, and chronic translation deficits, even without TDP-43 splicing failure. Its findings connect STMN2 protein instability with neuronal stress vulnerability and identify mRNA upregulation as a possible compensatory response in selected ALS contexts.

• Tacalcitol Monohydrate: VDR and NGF Research

  2026-08-27

  Tacalcitol monohydrate is a synthetic analog of vitamin D3 that activates VDR-directed transcription in dermatology and colorectal cancer research. Published cell studies link tacalcitol with CDKN1A induction, thymidylate synthase reduction, NGF induction, and increased 5-fluorouracil sensitivity.

• LCN2, Ferroptosis, and SA-AKI: AMPK/SIRT3/FOXO3a

  2026-08-27

  This study identifies Lipocalin-2 (LCN2) as a potential promoter of renal ferroptosis in sepsis-associated acute kidney injury through suppression of the AMPK/SIRT3/FOXO3a antioxidant pathway. By combining CLP-induced sepsis, LPS-stimulated HK−2 cells, genetic manipulation, and pathway rescue experiments, the work connects an established injury biomarker with a testable mechanism of oxidative renal damage.

• Biotin (Vitamin B7) for STING Assay Design

  2026-08-26

  Biotin (Vitamin B7) connects rigorous affinity-based detection with modern innate-immunity experiments. This article translates shrimp STING findings into practical decisions for protein labeling, nucleic-acid sensing assays, controls, and reagent handling.

8416 records 1/562 page Next 12345 下5页 Last page